Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet (2019) Vol. 394, Iss. 10215, pp. 2184-2196
Open Access | Times Cited: 1045

Showing 1-25 of 1045 citing articles:

Non-alcoholic fatty liver disease
Elizabeth E. Powell, Vincent Wai–Sun Wong, Mary E. Rinella
The Lancet (2021) Vol. 397, Iss. 10290, pp. 2212-2224
Closed Access | Times Cited: 1878
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 12, pp. 1113-1124
Open Access | Times Cited: 1337
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen, Émilie Crouchet, Thomas F. Baumert
Cells (2020) Vol. 9, Iss. 4, pp. 875-875
Open Access | Times Cited: 862
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai–Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 652
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 587
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 586
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 487
Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby, Emmanuel L. Gautier
Nature reviews. Immunology (2021) Vol. 22, Iss. 7, pp. 429-443
Open Access | Times Cited: 391
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 371
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 340
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
Helen Jarvis, Dawn Craig, Robert Barker, et al.
PLoS Medicine (2020) Vol. 17, Iss. 4, pp. e1003100-e1003100
Open Access | Times Cited: 335
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 322
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders
Daniel M. Chopyk, Arash Grakoui
Gastroenterology (2020) Vol. 159, Iss. 3, pp. 849-863
Open Access | Times Cited: 321
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 312
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 305
Molecular physiology of bile acid signaling in health, disease, and aging
Alessia Perino, Hadrien Demagny, Laura A. Velázquez‐Villegas, et al.
Physiological Reviews (2020) Vol. 101, Iss. 2, pp. 683-731
Open Access | Times Cited: 304
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Lulu Sun, Jie Cai, Frank J. Gonzalez
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 335-347
Closed Access | Times Cited: 283
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, et al.
Hepatology (2020) Vol. 72, Iss. 1, pp. 58-71
Closed Access | Times Cited: 269
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
Yasser Fouad, Imam Waked, Steven Bollipo, et al.
Liver International (2020) Vol. 40, Iss. 6, pp. 1254-1261
Open Access | Times Cited: 269
Role of liver sinusoidal endothelial cells in liver diseases
Jordi Gracia‐Sancho, Esther Caparrós, Anabel Fernández‐Iglesias, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 411-431
Closed Access | Times Cited: 263
The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Parth Trivedi, Shuang Wang, Scott L. Friedman
Cell Metabolism (2020) Vol. 33, Iss. 2, pp. 242-257
Open Access | Times Cited: 262
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
Nature Medicine (2021) Vol. 27, Iss. 7, pp. 1262-1271
Open Access | Times Cited: 255
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Claudia Fuchs, Michael Trauner
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 7, pp. 432-450
Closed Access | Times Cited: 254
NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 254
Page 1 - Next Page

Scroll to top